| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Nobuhiko Katunuma | |
| P2860 | cites work | Chymostatin, a new chymotrypsin inhibitor produced by actinomycetes | Q71527152 |
| 37 Structure, properties, mechanisms, and assays ofcysteine protease inhibitors: Cystatins and E-64 derivatives | Q71999767 | ||
| Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo | Q73077056 | ||
| Structure-based development of pyridoxal propionate derivatives as specific inhibitors of cathepsin K in vitro and in vivo | Q73445387 | ||
| Inhibition of intracellular cathepsin activities and suppression of immune responses mediated by helper T lymphocyte type-2 by peroral or intraperitoneal administration of vitamin B6 | Q73937042 | ||
| Critical role of cathepsin-inhibitors for autoantigen processing and autoimmunity | Q81100641 | ||
| IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells | Q81476292 | ||
| Lysosomal cysteine proteases: facts and opportunities | Q24535678 | ||
| Inhibition mechanism of cathepsin L-specific inhibitors based on the crystal structure of papain-CLIK148 complex | Q27620728 | ||
| The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity | Q27651464 | ||
| Crystal structure of cathepsin B inhibited with CA030 at 2.0-A resolution: A basis for the design of specific epoxysuccinyl inhibitors | Q27730182 | ||
| Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity | Q28591251 | ||
| Cathepsin L activity controls adipogenesis and glucose tolerance | Q34654358 | ||
| Action of rat liver cathepsin L on collagen and other substrates | Q42167985 | ||
| Structure-based design of specific cathepsin inhibitors and their application to protection of bone metastases of cancer cells | Q43857553 | ||
| Pepstatin A-sensitive aspartic proteases in lysosome are involved in degradation of the invariant chain and antigen-processing in antigen presenting cells of mice infected with Leishmania major. | Q54033906 | ||
| Switch of CD4+ T cell differentiation from Th2 to Th1 by treatment with cathepsin B inhibitor in experimental leishmaniasis. | Q54126242 | ||
| Biosynthesis of leupeptin | Q67276489 | ||
| Effect of proteinase inhibitors on intracellular processing of cathepsin B, H and L in rat macrophages | Q68325548 | ||
| Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro | Q70136099 | ||
| In vivo and in vitro evidence for the involvement of cysteine proteinases in bone resorption | Q70407077 | ||
| Inhibitions by E-64 derivatives of rat liver cathepsin B and cathepsin L in vitro and in vivo | Q71479486 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | enzyme | Q8047 |
| mechanism of action | Q3271540 | ||
| P304 | page(s) | 29-39 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | Proceedings of the Japan Academy, Series B | Q2675209 |
| P1476 | title | Structure-based development of specific inhibitors for individual cathepsins and their medical applications | |
| P478 | volume | 87 |
| Q55474273 | Affinity-Enhanced Luminescent Re(I)- and Ru(II)-Based Inhibitors of the Cysteine Protease Cathepsin L. |
| Q42380738 | Caging the uncageable: using metal complex release for photochemical control over irreversible inhibition |
| Q39004902 | Calpain research for drug discovery: challenges and potential |
| Q38025001 | Cancer-associated lysosomal changes: friends or foes? |
| Q26782938 | Cathepsin B is a New Drug Target for Traumatic Brain Injury Therapeutics: Evidence for E64d as a Promising Lead Drug Candidate |
| Q35906413 | Cathepsin L Mediates the Degradation of Novel APP C-Terminal Fragments. |
| Q39106632 | Cathepsin L silencing enhances arsenic trioxide mediated in vitro cytotoxicity and apoptosis in glioblastoma U87MG spheroids |
| Q36218199 | Cathepsin L targeting in cancer treatment. |
| Q51498595 | Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast Cancer Progression: A Preliminary Report. |
| Q26827307 | Cysteine cathepsins: their role in tumor progression and recent trends in the development of imaging probes |
| Q91690107 | Cysteine-type cathepsins promote the effector phase of acute cutaneous delayed-type hypersensitivity reactions |
| Q36256794 | Discovery of Reactive Microbiota-Derived Metabolites that Inhibit Host Proteases |
| Q39067283 | Emerging challenges in the design of selective substrates, inhibitors and activity-based probes for indistinguishable proteases |
| Q55530715 | Identification of proteins with potential osteogenic activity present in the water-soluble matrix proteins from Crassostrea gigas nacre using a proteomic approach. |
| Q28534433 | Identification of semicarbazones, thiosemicarbazones and triazine nitriles as inhibitors of Leishmania mexicana cysteine protease CPB |
| Q87421342 | Inhibition of cysteine cathepsin B and L activation in astrocytes contributes to neuroprotection against cerebral ischemia via blocking the tBid-mitochondrial apoptotic signaling pathway |
| Q37973268 | Microbial and fungal protease inhibitors--current and potential applications |
| Q38268345 | Proteolysis mediated by cysteine cathepsins and legumain-recent advances and cell biological challenges |
| Q50091548 | Ru(ii) polypyridyl complexes as photocages for bioactive compounds containing nitriles and aromatic heterocycles |
| Q40699809 | Streptococcus oralis Induces Lysosomal Impairment of Macrophages via Bacterial Hydrogen Peroxide |
| Q37998958 | The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles |
Search more.